Other Specified or Unspecified Depressive Disorders
(formerly Depressive Disorder NOS)

Article written and reviewed by Dr Luca Moretti

The categories other specified depressive disorder and unspecified depressive disorder are used in the DSM-5-TR when symptoms characteristic of a depressive disorder predominate and cause clinically significant distress or functional impairment, but all requirements for a more specific depressive disorder are not met. They are not synonyms for mild depression and do not automatically indicate a transient or risk free presentation.

These categories replaced much of the former DSM-IV category of depressive disorder not otherwise specified, or NOS. In other specified depressive disorder, the clinician states the reason why the presentation does not meet a more defined diagnosis; in unspecified depressive disorder, the reason is not stated, often because the available information does not permit more precise characterization.

The DSM-5-TR includes examples of other specified presentations, including recurrent brief depression, short duration depressive like episodes and depressive like episodes with insufficient symptoms. The terminology of the latter two presentations was officially updated by the American Psychiatric Association in September 2025 to emphasize that the presentation resembles a depressive episode but lacks one of the required diagnostic elements.

ICD-11 includes analogous but not perfectly overlapping categories: other specified depressive disorders, code 6A7Y, and depressive disorder, unspecified, code 6A7Z. Diagnosis and coding should therefore be interpreted in the context of the classification system being used, without treating DSM-5-TR and ICD-11 as literal translations of one another.

There is no single epidemiological estimate applicable to these categories. The literature on so called subthreshold depression uses widely different definitions regarding number of symptoms, duration, screening instruments and exclusion of major depression, so prevalence estimates vary greatly. DSM other specified and unspecified categories also do not coincide with all definitions of subclinical depression used in epidemiological studies.

The clinical relevance is nevertheless substantial: depressive symptoms below the threshold for major depressive disorder may be associated with reduced quality of life, functional impairment, health care use and an increased likelihood of future depressive episodes in some groups. This association does not mean, however, that every subthreshold presentation is inevitably a prodromal phase of major depression.

Etiology, Pathogenesis and Pathophysiology

Other specified and unspecified categories do not identify a single biologically homogeneous entity and therefore do not have a specific etiological cause. They include different presentations united by failure to fully meet requirements for other depressive disorders despite causing clinically significant impact.

Vulnerability to depressive symptoms arises from interactions among genetic predisposition, development, stress, sleep, physical illness, social factors and psychological processes. Depression has a polygenic architecture, but no genetic variant or combination of variants can distinguish other specified depressive disorder from major depression or normal mood variability in an individual patient.

A family history of depression and other mood disorders may increase vulnerability but is not a diagnostic requirement. Adverse events, early trauma, social isolation, financial difficulties and chronic stress are associated with a higher risk of depressive symptoms, yet they are neither necessary nor sufficient causes.

Neurobiological hypotheses involve monoaminergic systems, glutamate, synaptic plasticity, neurotrophic factors and brain networks involved in reward and emotion regulation. These mechanisms derive mainly from research on major depression, and no specific profile characterizing the residual categories has been identified.

Reduced sensitivity to reward may contribute to anhedonia and reduced motivation, while negative cognitive biases and rumination may perpetuate sadness and self devaluation. These processes are dimensional and are observed at varying intensity even below conventional diagnostic thresholds.

Sleep and circadian rhythms are closely associated with depressive symptoms. Persistent insomnia may increase the risk of depression and worsen functioning; conversely, depression may alter sleep onset, sleep maintenance and the sleep wake rhythm. A concomitant sleep disorder should therefore be investigated and treated when present.

Studies of subthreshold forms have described group level neuroimaging differences, but these findings are nonspecific and have no individual diagnostic value. The presence of a connectivity or structural abnormality observed in research does not demonstrate the cause of an individual patient’s symptoms.

Inflammatory and neuroendocrine markers have also been studied across the depressive continuum, but results are influenced by obesity, smoking, medications, physical activity and concomitant illnesses. No blood or hormonal measurement identifies other specified depressive disorder.

A useful pathophysiological concept is the dimensional nature of many depressive symptoms. Mood, pleasure, energy, concentration and sleep may deteriorate progressively without meeting categorical thresholds for duration or symptom number. Diagnostic classifications establish operational thresholds to improve reliability, but distress and disability do not suddenly appear only when a numerical threshold is crossed.

This continuity does not mean that all subthreshold depression represents attenuated forms of the same disease. Partial symptoms may occur in anxiety disorders, bereavement, adjustment disorder, medical conditions, substance use, bipolar disorders and many other situations. Pathogenesis should therefore be interpreted only after a complete differential diagnosis.

Medications and substances may cause or worsen depressive symptoms. When a sufficiently demonstrated pathophysiological relationship exists between exposure and the syndrome, the appropriate diagnosis may be substance or medication induced depressive disorder rather than a primary residual category.

Similarly, when a medical condition is considered directly responsible for the depressive syndrome, depressive disorder due to another medical condition should be considered. The mere presence of a chronic disease is not sufficient to establish causality.

There are therefore no diagnostic biomarkers for these categories. Uncertainty is not resolved by magnetic resonance imaging, genetic testing, cortisol measurement or inflammatory panels, but through careful assessment of phenomenology, duration, course and alternative causes.

Clinical Manifestations

The clinical presentation may include depressed mood, anhedonia, sleep and appetite changes, fatigue, cognitive difficulties, retardation or agitation, self devaluation and thoughts of death, but the number of symptoms, their duration or the overall configuration does not meet the requirements for a more specific depressive diagnosis.

The DSM-5-TR describes several illustrative presentations for the other specified category. These are official formulations showing why the requirements for a more defined disorder are not met, but they do not represent the entire range of possible clinical presentations.

• Recurrent brief depression: periods with depressed mood and at least four additional depressive symptoms lasting 2 to 13 days, occurring at least once a month for at least twelve consecutive months and not exclusively in relation to the menstrual cycle, in a person who has never met criteria for another depressive or bipolar disorder and who does not currently meet active or residual criteria for a psychotic disorder.
• Short duration depressive like episodes (short-duration depressive-like episodes): depressed affect and at least four of the other eight symptoms of a major depressive episode, associated with clinically significant distress or impairment, persisting for 4 to 13 days, in a person who has never met criteria for another depressive or bipolar disorder and who does not currently meet active or residual criteria for a psychotic disorder.
• Depressive like episode with insufficient symptoms (depressive-like episode with insufficient symptoms): depressed affect associated with at least one of the other eight symptoms of a major depressive episode, with clinically significant distress or impairment, persisting for at least two weeks, in a person who has never met criteria for another depressive or bipolar disorder and who does not currently meet active or residual criteria for a psychotic disorder.

In recurrent brief depression, episodes are too short to meet the temporal requirement for a major depressive episode but recur over time. Diagnosis requires distinguishing these episodes from physiological mood fluctuations, symptoms exclusively related to the menstrual cycle, bipolar disorders, substances and other conditions.

In short duration depressive like episodes, the symptom constellation may resemble major depression, but the minimum duration of two weeks is not met. Distress may nevertheless be intense, and suicide risk should be assessed according to the clinical presentation rather than duration alone.

In depressive like episodes with insufficient symptoms, the issue is instead the number of symptoms: duration reaches at least two weeks, but the five manifestations required for a major depressive episode are not present. The patient may nevertheless experience substantial impairment if the few symptoms present are intense.

The unspecified category is used when the depressive presentation is clinically significant but the clinician does not state the reason why it fails to meet a more precise diagnosis. This may occur when available time is limited, information is incomplete or the history cannot yet be reconstructed reliably.

The history should explore the full spectrum of depressive symptoms and define their duration, frequency, intensity and functional impact. Apparently mild symptoms may be highly disabling when recurrent, whereas intense but extremely brief symptoms may require a formulation different from major depression.

It is essential to assess suicidal ideation, self injury, previous attempts, hopelessness, agitation and access to lethal means. Failure to meet criteria for major depressive disorder does not eliminate suicide risk and does not justify a less thorough assessment.

A history of mania or hypomania should be investigated systematically. Subthreshold depressive symptoms may belong to a bipolar disorder or residual bipolar presentation; inappropriate use of a depressive category in the presence of bipolarity may affect treatment.

Bereavement and other stressful events should be assessed without automatic assumptions. The presence of a stressor does not establish adjustment disorder, and bereavement does not exclude a clinical depressive syndrome. The distinction depends on phenomenology, temporal relationship and the specific requirements of the categories considered.

Anxiety disorders, PTSD, eating disorders, chronic pain and medical conditions may present with associated depressive symptoms. A residual diagnosis should be made only when the depressive domain actually represents the predominant clinical presentation.

Mental status examination may show depressed affect, reduced reactivity, slowing, anxiety, rumination and negative cognitions, but there is no specific objective finding. The patient may appear essentially normal between brief episodes, making reconstruction of the history particularly important.

Investigations and Diagnosis

The diagnosis is clinical and is made after establishing that depressive symptoms cause distress or impairment but do not meet the requirements for a more specific category. No laboratory test, questionnaire or instrumental examination independently defines these diagnoses.

The first step is to verify criteria for major depressive disorder, persistent depressive disorder and other relevant depressive disorders. A residual category should not be used as a shortcut when an appropriate diagnostic assessment has not been completed.

For other specified depressive disorder, the clinician should document the specific reason why the presentation does not meet a more defined diagnosis. The formulation therefore becomes part of the diagnosis, for example “other specified depressive disorder, short duration depressive like episode” (short-duration depressive-like episode).

Terminology should reflect the September 2025 DSM-5-TR update, which introduced the English suffix -like into the names of some presentations to clarify that they resemble a defined disorder or episode but lack one requirement. The older names should not be used as though they had remained unchanged.

For unspecified depressive disorder, by contrast, the clinician does not state the reason why criteria are not met. This choice is particularly appropriate when the available information is insufficient for a more precise diagnosis but the clinically significant depressive presentation is evident.

Differential diagnosis with bipolar disorder is a priority. Previous hypomanic or manic episodes change the formulation and should be investigated with specific questions about energy, activity, need for sleep, grandiosity, speech and impulsivity.

Adjustment disorder should be considered when symptoms are related to an identifiable stressor and meet the requirements for that category. Adjustment disorder should not automatically be diagnosed every time depression follows a stressful event.

Persistent depressive disorder requires a specific chronic history; recurrent brief depression is instead characterized by repeated but brief episodes. Chronology therefore distinguishes conditions that may appear similar in a single interview.

Conditions induced by substances or medications should be excluded. Alcohol, sedatives, stimulants and other agents may alter mood, while some medications may contribute to depressive symptoms in susceptible individuals. The temporal relationship between exposure and symptoms informs diagnosis.

Endocrine, neurological, hematological and systemic diseases may produce fatigue, insomnia, loss of appetite or cognitive difficulties. Tests such as complete blood count, TSH, electrolytes, renal and liver function, vitamin B12 or other investigations are ordered when the history or physical examination suggests an alternative diagnosis.

Neuroimaging, EEG and neuropsychological testing are not routinely indicated. They become appropriate in the presence of neurological signs, cognitive deterioration, seizures, atypical onset or other findings suggesting nervous system disease.

Scales such as the PHQ-9 may quantify symptoms and support monitoring, but questionnaire thresholds do not automatically correspond to DSM categories. A subthreshold score does not amount to other specified depressive disorder, and a high score does not replace clinical diagnosis.

Assessment should also define suicide risk. An insufficient number of symptoms does not protect against thoughts of death or suicidal behavior; management of urgency depends on intent, planning, previous attempts, protective factors and the overall context.

Follow up may change the diagnosis. An initially brief or incomplete presentation may resolve, recur, later meet requirements for major depression, or be reinterpreted in light of new information. This possibility does not mean that a residual category is always a prodrome of a more severe disorder.

Treatment and Prognosis

Treatment depends on severity, duration, recurrence, risk, impairment and differential diagnosis. There is no medication approved or treatment sequence specific to the general label of other specified or unspecified depressive disorder. Decisions should be guided by the syndrome actually present and the evidence available for similar presentations.

In nonsevere subthreshold forms, psychological and structured self management interventions may be appropriate. Meta analyses of subclinical depression have documented benefits of psychological interventions on symptoms and, in some populations, a reduced likelihood of subsequent major depression. These findings should not be transferred automatically to every residual category, but they support the usefulness of early intervention when clinically indicated.

Cognitive behavioral therapy, behavioral activation and other validated psychological interventions may be used according to symptoms and preferences. Goals may include reducing rumination, resuming rewarding activities, regulating sleep and managing stress and interpersonal problems.

Routine use of antidepressants for every form of subthreshold depression is not supported by robust evidence. Reviews specifically addressing subthreshold forms have found limited and inconclusive evidence for pharmacological treatment, while modern guidelines recommend matching intervention intensity to severity and preferences.

When a patient has a presentation close to the threshold for major depression, severe impairment, high risk or persistence despite initial interventions, pharmacotherapy may be assessed individually after bipolarity and other causes have been excluded. A residual diagnosis should neither automatically require nor prohibit an antidepressant.

Sleep, physical activity, alcohol and substance use, social support and concomitant illnesses should be addressed in the treatment plan. Physical exercise has evidence in depression and may be integrated when appropriate, but it does not replace necessary clinical interventions in more impaired patients.

When the presentation is predominantly related to an anxiety disorder, trauma, a substance or a medical condition, treatment should also target the identified cause or comorbidity. A residual depressive category should not obscure the dominant pathological process.

Suicide risk requires a specific plan regardless of the categorical diagnosis. Ideation with intent, planning, a recent attempt or inability to ensure safety may require urgent assessment and a higher level of care.

Response should be monitored over time. Symptom reduction, recovery of functioning and prevention of progression to more severe episodes are relevant goals, but monitoring also serves to verify whether the initial diagnosis remains appropriate.

Prognosis is heterogeneous. Some brief presentations resolve without evolving into more persistent disorders; others recur; some patients with subthreshold symptoms experience a major depressive episode over time. Prospective studies show an increased average risk of major depression in populations with subthreshold symptoms, but do not allow certain individual prediction.

At the group level, a less favorable prognosis is associated with greater symptom burden, persistence, recurrent episodes, anxiety comorbidity, substance use, adverse events and functional impairment. The presence of these factors should prompt closer follow up, not deterministic labeling.

Early treatment may reduce distress and disability even when major depression is not yet present. The aim is not to “medicalize” every episode of sadness, but to distinguish normal emotional variability from persistent or recurrent symptoms that produce clinically significant consequences.

Complications

The most important complication is suicidal behavior. Ideation and attempts may occur even in people who do not meet the number or duration of symptoms required for a major depressive episode. Risk assessment should therefore be based on the patient rather than on the diagnostic label alone.

Persistent or recurrent depressive symptoms may cause social and occupational impairment, reduced productivity, isolation and academic difficulties. The impact may become substantial even when each individual episode is brief.

Some patients may subsequently develop major depressive disorder or another mood disorder. This risk is higher in some groups with subthreshold depression, but progression is not inevitable and should not be described as a certain consequence.

Use of alcohol or other substances to manage insomnia, anxiety or sadness may worsen the course and increase impulsivity and suicide risk. Substance comorbidity may also make it more difficult to determine whether symptoms are primary or induced.

Chronicity of initially incomplete symptoms may produce progressive loss of functioning and require diagnostic reassessment. Persistence does not necessarily mean transformation into major depression: persistent depressive disorder, another disorder or a different formulation may emerge.

One clinical risk is underestimation because of the “subthreshold” label. A patient with few symptoms but intense hopelessness or impairment may receive insufficient care if the clinician focuses only on the number of criteria.

The opposite risk is overdiagnosis of normal emotional reactions. Transient sadness, nonpathological grief and fluctuations related to everyday events should not automatically be transformed into a depressive disorder. Clinically significant distress, impairment and a coherent pattern are essential.

A provisional diagnosis that is not reassessed may persist in the record even when the subsequent course permits a more specific classification. Longitudinal follow up reduces the risk of treatment errors and improves diagnostic consistency.

Overall, complications depend less on the residual category name and more on severity, recurrence, suicidality, comorbidity and loss of functioning. These domains should be monitored systematically during treatment.

Bibliography
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing; 2022.
2. American Psychiatric Association. DSM-5-TR Update, September 2025. American Psychiatric Association; 2025.
3. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization; 2024.
4. Malhi GS et al. Depression. The Lancet. 407(10540), 2026: 1738-1756.
5. Marx W et al. Major depressive disorder. Nature Reviews Disease Primers. 9(1), 2023: 44.
6. Lam RW et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry. 69(9), 2024: 641-687.
7. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE Guideline NG222. National Institute for Health and Care Excellence; 2022, reviewed 2026.
8. Cuijpers P et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 22(1), 2023: 105-115.
9. Cuijpers P et al. Psychotherapy for subclinical depression: meta-analysis. British Journal of Psychiatry. 205(4), 2014: 268-274.
10. Cameron IM et al. Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder. Journal of Affective Disorders. 166, 2014: 48-58.
11. Volz HP et al. Subthreshold depression: concept, operationalisation and epidemiological data. A scoping review. International Journal of Psychiatry in Clinical Practice. 27(1), 2023: 92-106.
12. Noetel M et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 384, 2024: e075847.
13. Cuijpers P et al. Psychological interventions to prevent the onset of major depression in adults: a systematic review and individual participant data meta-analysis. Lancet Psychiatry. 11(12), 2024: 990-1001.